story of the week
Anti–PD-1 and Anti–CTLA-4 Therapy in Operable NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Operable Non-Small Cell Lung Cancer: The Phase 2 Randomized NEOSTAR Trial
Nat. Med. 2021 Feb 18;[EPub Ahead of Print], T Cascone, WN William, A Weissferdt, CH Leung, HY Lin, A Pataer, MCB Godoy, BW Carter, L Federico, A Reuben, MAW Khan, H Dejima, A Francisco-Cruz, ER Parra, LM Solis, J Fujimoto, HT Tran, N Kalhor, FV Fossella, FE Mott, AS Tsao, G Blumenschein, X Le, J Zhang, F Skoulidis, JM Kurie, M Altan, C Lu, BS Glisson, LA Byers, YY Elamin, RJ Mehran, DC Rice, GL Walsh, WL Hofstetter, JA Roth, MB Antonoff, H Kadara, C Haymaker, C Bernatchez, NJ Ajami, RR Jenq, P Sharma, JP Allison, A Futreal, JA Wargo, II Wistuba, SG Swisher, JJ Lee, DL Gibbons, AA Vaporciyan, JV Heymach, B SepesiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.